The Nifty Pharma index has fallen 11.52 per cent in the last six months. All the heavyweights of the industry – Sun, Wockhardt, Lupin, Aurobindo – have shed value as investors fear the United States may restrict the import of inexpensive medicine.
The US is where these companies make money. India, under stringent price controls, does not hold much attraction for them. Now, with President Donald Trump all out to promote “Make in America”, Indian pharmaceutical majors could be in for a rough ride, it is feared.
Pharmacies in the US are allowed to hand out generic versions of the prescribed medicine
Disclaimer: These are personal views of the writer. They do not necessarily reflect the opinion of www.business-standard.com or the Business Standard newspaper